Navigation Links
ERT to Announce 2009 Third Quarter Results on October 29, 2009
Date:10/21/2009

PHILADELPHIA, Oct. 21 /PRNewswire-FirstCall/ -- ERT (Nasdaq: ERES), a leading provider of centralized ECG, ePRO, eClinical technology, and other services to the biopharmaceutical, medical device, and related industries, announced today that it will release its results for the 2009 third quarter on Thursday, October 29, 2009 after the market closes. After the release, the Company will host a conference call at 5:00 PM EDT that day.

For the conference call, interested participants should dial 1-800-860-2442 when calling within the United States or 1-412-858-4600 when calling internationally. There will be a playback available as well. To listen to the playback, please call 1-877-344-7529 when calling within the United States or 1-412-317-0088 when calling internationally.

This call is being webcast by MultiVu and can be accessed at ERT's website at www.ert.com. The webcast may also be accessed via the direct link at http://www.videonewswire.com/event.asp?id=63252. The webcast can be accessed for up to one year on either site.

Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of technology and services to the biopharmaceutical, medical device, and related industries. The Company is the market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The Company also provides technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis, and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, including but not limited to 2009 financial guidance, involve a number of risks and uncertainties such as the company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope, and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

SOURCE ERT


'/>"/>
SOURCE ERT
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Myriant Technologies LLC Announces Appointment of Science Advisory Board Members
2. Winners Announced in 2009 Collegiate Inventors Competition(R)
3. BioWa and NKTT Announce Licensing of BioWas POTELLIGENT(R) Technology For Use in Antibody Research and Development
4. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
5. Professional Pricing Society Announces Educational Partnership with Vendavo -- "PPS Accepting Vendavo Pricing Knowledge Series Awards to Certified Pricing Professional Program"
6. Lotus Pharmaceuticals, Inc. Announces 2010 Growth Strategy
7. Vasogen Inc. and IntelliPharmaCeutics Jointly Announce Shareholder Approval of Plan of Arrangement and Merger
8. Neurobiological Technologies Announces Intent to File Form 25 to Delist Common Stock From the NASDAQ Capital Market
9. China Medical Technologies Announces the SFDA Approval for its SPR System
10. Fate Therapeutics Announces Creation of Small Molecule Platform for Commercial Scale Reprogramming
11. avVaa World Health Care Products Inc. Announces Access via Social Media Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... IsoPlexis ... against cancer, autoimmune disease and more through a single-cell precision engineering platform, today ... analysis platform developed in the laboratory of Dr. James Heath at the ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... Cambridge, MA (PRWEB) , ... March 27, 2017 ... ... published a method to engineer scalable and customizable vascular grafts in JoVE’s Video ... that may lead to new and improved ways of treating coronary artery disease ...
(Date:3/24/2017)... MiMedx Group, Inc. (NASDAQ: MDXG), the leading ... allografts and patent-protected processes to develop and market advanced ... today  that it will present at the Needham Healthcare ... Parker H. "Pete" Petit, Chairman and CEO, Michael ... Cashman , EVP and Chief Commercialization Officer, and ...
Breaking Biology Technology:
(Date:3/7/2017)... LAKE CITY , March 7, 2017   ... that help top global companies identify the best talent, ... as Chief Sales Officer (CSO) and Diana ... Kucer,s appointments round out a seasoned executive team poised to ... and beyond, building on a year of record bookings ...
(Date:3/2/2017)... 2, 2017 Who risk to be deprived ... the full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE ... FIELD? Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:2/28/2017)... News solutions for biometrics, bag drop and ... ... to 16 March, Materna will present its complete end-to-end passenger ... is a real benefit for passengers. To accelerate the whole ... touch point solutions to take passengers through the complete integrated ...
Breaking Biology News(10 mins):